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PreviewsBecause one of the PI3Ki resistant lines
in the current paper was ER negative,
additional mechanisms likely underlie
persistent CDK4 activation in ER-negative
PI3Ki-resistant breast cancer lines.
Indeed, a comprehensive elucidation of
themechanisms underlying persistent cy-
clin D1 expression and CDK4 activity in
the presence of PI3Ki and the down-
stream events mediating cell survival
and proliferation may provide a ‘‘suite’’
of targets warranting exploration in com-
bination with PI3Ki in the future. In the
absence of a detailed understanding of
the underlying mechanisms, the most
attractive clinical option is to explore the
combination of PI3K and CDK4/6 inhibi-
tors (Figure 1). Direct targeting of CDK4/
6 or critical downstream nodes has the
potential to bypass the multiple resis-
tance mechanisms that integrate at cyclin
D1 expression and CDK4 activation.
The therapeutic implications of the cur-
rent study are promising and warrant
exploration in clinical trials. First, the com-
bination of PI3K and CDK4/6 inhibitors
may be synergistic in different contextsand genomic backgrounds. Second, the
addition of CDK4/6 inhibitors to xenograft
models that progressed on PI3Ki effec-
tively inhibited tumor growth, suggesting
that CDK4/6 inhibitors can prevent the
emergence as well as overcome resis-
tance to PI3Ki. Third, persistent pRB rep-
resents a potential biomarker to identify
patients in which addition of CDK4/6
inhibitors to ongoing PI3Ki treatment
may be beneficial. Fourth, in preclinical
studies, the combination of PI3K and
CDK4/6 inhibitors appears to be well
tolerated. Interestingly, clinical trials are
underway to test the efficacy of CDK4/6
inhibitors together with rapalogs and aro-
matase inhibitors (https://clinicaltrials.
gov) to determine whether the combina-
tion of other PI3K pathway and CDK4/6
inhibitors may benefit patients who have
relapsed on prior hormone or PI3K tar-
geted therapies.
In conclusion, this study adds to the
growing number of rational combinations
with PI3Ki that could fulfill the promise of
targeting the PI3K pathway in the clinic.
Nevertheless, it remains critical to iden-Cancer Ctify and refine biomarkers that will allow
assignment to combination treatments
that would lead to the most efficacious
response and to continue to identify novel
drug combinations that would be well
tolerated in patients.
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The diffuse-type histologic variant of gastric cancer is characterized by highly invasive growth patterns
and lack of cellular cohesion. Two recent studies have identified highly recurrent mutations of the gene
encoding the small GTPase RhoA and suggest that RhoA activity may have a tumor suppressive role in
this disease.Gastric cancer is the third leading cause
of cancer mortality worldwide and,
when diagnosed, carries a dismal prog-
nosis. Although gastric carcinoma has
marked heterogeneity, the two most
salient subtypes are intestinal gastric
cancer (IGC) and diffuse gastric cancer
(DGC). The dichotomization of IGCand DGC emerged following recognition
of their distinct histopathologic growth
patterns. IGC is the more common
variant and typically emerges following
Helicobater pylori infection, which leads
to atrophic gastritis, intestinal meta-
plasia, dysplasia, and finally carcinoma.
Similar to most adenocarcinomas, IGCtypically shows cohesive groups of
tumor cells with a glandular architecture.
DGC, by contrast, owes its name to its
characteristic lack of cellular cohesion,
invasion throughout the stroma, and
poor cellular differentiation (often with a
signet-ring cell morphology). Clinically,
DGC’s propensity for invasion translatesell 26, July 14, 2014 ª2014 Elsevier Inc. 9
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Previewsinto early metastasis and poor survival.
Moreover, unlike in IGC where tumors
with ERBB2-amplification are treated
with trastuzumab, we lack effective tar-
geted therapies for DGC.
In addition to their histopathologic fea-
tures, there are underlying biologic and
genomic distinctions between DGC and
IGC. A key finding shaping our under-
standing of DGC was the discovery that
families with a hereditary form of DGC
carried a mutation in CDH1, which en-
codes E-cadherin (Guilford et al., 1998).
Beyond hereditary DGC, the vastly more
common sporadic form of DGC has also
been associated with E-cadherin loss,
either through somatic mutation or pro-
moter hypermethylation. Recently, a pair
of studies published in Nature Genetics
expands our understanding of DGC by
describing novel recurrent mutations of
RHOA, encoding the small GTPase
RhoA, in 14.3%–25.3% of DGC patients
(Kakiuchi et al., 2014; Wang et al., 2014).
Wang et al. (2014) performed whole-
genome sequencing, DNA copy number,
gene expression, and DNA methylation
analyses of 100 tumor and nontumor
paired samples, spanning both IGC and
DGC. Their analysis revealed frequent
mutations in TP53 in both subtypes,
ARID1A in EBV-related or microsatellite
instability-related cancers, and CDH1 in
DGC. RHOA mutation was identified
recurrently within DGC and, following
sequencing in a larger DGC cohort, was
found in 14 of 98 DGC patients (14.3%).
Kakiuchi et al. (2014) initially performed
whole-exome sequencing within 30
DGCs and focused sequencing in another
57 cases, findingRHOAmutations in 22 of
87 (25.3%) cases.
These findings and similar results
emerging from The Cancer Genome Atlas
study of gastric adenocarcinoma (unpub-
lished data) implicate RHOA as a novel
candidate driver of DGC. RhoA is a
member of the Rho family of small
GTPases-Ras-like proteins that act as an
intermediary between cell surface recep-
tors and different intracellular signaling
proteins. Similar to other GTPases, RhoA
cycles between an inactive, GDP-bound
configuration and an active GTP-bound
configuration that interacts with down-
stream effectors, such as ROCK, that
impact the structure and dynamics of
the actin cytoskeleton, cell migration,
cytokinesis, and the cell cycle. RhoA10 Cancer Cell 26, July 14, 2014 ª2014 Elsevoverexpression has been observed in
various cancers, and RhoA activity has
been implicated in tumorigenesis and
tumor cell invasion (Karlsson et al., 2009).
Given the characteristic invasive
growth patterns that are a hallmark of
DGC, mutations in RHOA could be pre-
dicted to lead to constitutive activation
of RhoA, enhancing activity of down-
stream mediators and increasing cellular
invasion. Among the mutations in RHOA
identified by these two studies, one led
to a truncated protein, while the others
were missense events with dramatic clus-
tering in the amino terminal portion of the
protein. However, the specific RHOA
mutations identified in DGC were not at
sites analogous to oncogenic mutations
in RAS-family GTPases that cause RAS
to become locked into its active-GTP
bound state. These RHOA mutations
were noted in hotspot sites, including
Y42C, G17E, R5Q/W, and L57V. The
most common alteration, Y42C, seen in
14 cases, lies in the effector-binding re-
gion of RhoA. Although not previously
identified in cancer, the Y42C substitution
in RhoA had been evaluated in earlier
biochemical studies, which revealed
attenuated activation of protein kinase N
(Sahai et al., 1998). RhoA-Y42 notably
corresponds to Y40 on HRas, where
mutations selectively reduce HRas acti-
vation of RAF, but not other RAS effectors
(Joneson et al., 1996), suggesting that the
Y42 RHOA mutation may similarly modu-
late RhoA activity. Intriguingly, G17E
mutations of RHOA were identified in
five patients. Recent genomic sequencing
studies in T cell neoplasms identified
highly recurrent RHOA G17V mutations
and demonstrated functionally that these
mutants fail to bind GTP and act in
a dominant-negative fashion to inhibit
RhoA GTP loading (Palomero et al.,
2014; Sakata-Yanagimoto et al., 2014;
Yoo et al., 2014).
To functionally interrogate these novel
RHOA mutations found in DGC, Kakiuchi
et al. (2014) studied several cancer cell
lines harboring RHOA mutations: the
OE19 cell line (adenocarcinoma of the
gastric cardia), the breast cancer cell line
BT474, and the colorectal cancer line
SW948. They showed that small inter-
fering RNA (siRNA)-mediated silencing of
RHOA significantly impairs in vitro prolif-
eration in these mutant cell lines but
does not similarly impact gastric cancerier Inc.cell lines with wild-type RHOA. Further-
more, they demonstrated that reintroduc-
tion of the codon 17 or 42 RHOAmutants,
but not reintroduction of wild-type RHOA
rescued cell proliferation effects of
RHOA siRNA, suggesting tumor-promot-
ing activity for these RHOA mutants.
The results from Wang et al. (2014)
provide additional insights into the poten-
tial role of mutant RHOA. Using a Rho
binding domain assay to immunoprecipi-
tate RhoA-GTP, the authors showed that
both the Y42C and L57V mutants sig-
nificantly attenuate the GTP-associated
form compared to wild-type protein,
indicating a potential defect in RhoA
activation with these mutants. They
further utilized primary mouse intestinal
organoids to study the impact of RHOA
mutants Y42C and L57V upon anoikis
(cell death induced when anchorage-
dependent cells detach from the sur-
rounding extracellular matrix). Inhibition
of anoikis may represent a key require-
ment for DGC, because loss of E-cad-
herin leading to reduction in cellular
adhesion has been shown to result in
acute cell death via anoikis (Kantak and
Kramer, 1998). With dissociation of the
mouse intestinal organoids, the intro-
duction of Y42C or L57V RHOA mutants
enhanced organoid reformation. While
treatment with ROCK inhibitor Y-27632
also enhanced colony growth, wild-type
RHOA induction reduced the colony
forming efficiency.
Through comprehensive genomic char-
acterization, these studies demonstrate
that, along with CDH1 mutations, RHOA
mutations are quite common in DGC but
not in other variants of gastric cancer.
Intriguingly, these results suggest amodel
whereby wild-type RhoA activity has a
tumor suppressive role in the pathophys-
iology of DGC and that RHOA mutations
inhibit this tumor suppressive function,
suggesting these mutants are not merely
loss of function, but may repress RhoA
activity. It remains to be clarified, how-
ever, whether RHOA mutations merely
attenuate physiologic RhoA activity or,
alternatively, if these mutations result in
a gain of function. Given the pressing
need for new therapeutic targets for
DGC, further research will be required to
determine if the activity of these novel
RHOA mutants and the deleterious role
of RhoA activity in this disease can be ex-
ploited as a therapeutic vulnerability.
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Ibrutinib is a potent inhibitor of Bruton’s tyrosine kinase (BTK). Studies published in the New England Journal
of Medicine report that patients with chronic lymphocytic leukemia (CLL) have durable responses to ibrutinib,
but they also describe the advent of bypass mutations that result in ibrutinib resistance and progressive
disease.Signaling through the B cell receptor
(BCR) can promote tumor cell survival in
B cell malignancies, including chronic
lymphocytic leukemia (CLL), mantle cell
lymphoma (MCL), and the activated B
cell-like (ABC) subtype of diffuse large
B cell lymphoma (DLBCL). The BCR
consists of immunoglobulin heavy (IgH)
and light (IgL) chains coupled to a
CD79A-CD79B heterodimer that trans-
duces signals by engaging downstream
nonreceptor kinases, including Bruton’s
tyrosine kinase (BTK) (Young and Staudt,
2013). These kinases offer a wealth of
therapeutic targets, and drugs targeting
SYK, BTK, and phosphatidylinositol 3-ki-
nase (PI3K) are in clinical trials to evaluate
their efficacy against a variety of human
lymphomas.
Ibrutinib (PCI-32765, Imbruvica) is an
irreversible inhibitor of BTK that works
by forming a covalent bond with cysteine
481 (C481) in the BTK active site,
rendering the drug potent and highly
selective, thereby limiting side effects.
Several clinical trials are now evaluating
ibrutinib in human lymphomas, and thedrug has been granted breakthrough sta-
tus by the US Food and Drug Administra-
tion for the treatment of refractory MCL
and high-risk CLL. Because activating
mutations in BTK have not been observed
in these lymphomas, it is likely that up-
stream signaling from the BCR is the
culprit.
BCR expression is obligatory in normal
B cells and most malignant B cells. In
CLL, analysis of the antigen recognition
portion of the BCR revealed preferential
usage of a small subset of Ig variable
gene segments, suggesting that the
BCRs may react with an antigen. In sup-
port of this notion, different CLL and
MCL patients can have ‘‘stereotypic’’
BCRs with virtually identical antigen
recognition sites (Agathangelidis et al.,
2012). The first direct evidence for BCR-
dependent survival signaling was ob-
tained in ABC DLBCL (Davis et al.,
2010). RNA interference screening re-
vealed that BCR components and down-
stream signaling effectors (SYK, BTK,
and PLCg2) are required for ABC DLBCL
cell survival. Microscopy revealed BCRclusters on the surface of ABC DLBCL
cells that are similar to those induced by
antigen engagement of the BCR in normal
B cells. Recurrent gain-of-function muta-
tions in CD79A and CD79B augment
BCR signaling in a subset of ABC DLBCL
cases, providing genetic evidence that
the BCR pathway is important in the path-
ogenesis of this lymphoma subtype. The
‘‘chronic active’’ form of BCR signaling
in ABC DLBCL is sensitive to ibrutinib
and therefore may be mechanistically
similar to BCR signaling in CLL and MCL
(Figure 1).
Three reports in the New England Jour-
nal of Medicine examined ibrutinib treat-
ment in CLL patients. The first study
evaluated ibrutinib monotherapy in pa-
tients with relapsed and high-risk CLL
versus ofatumumab, an anti-CD20 anti-
body that is the current standard therapy
for these patients. Ibrutinib produced a
70% response rate compared with only
21% for ofatumumab, and ibrutinib was
also superior to ofatumumab with respect
to progression-free and overall survival
(Byrd et al., 2014).ell 26, July 14, 2014 ª2014 Elsevier Inc. 11
